Escherichia coli ( DrugBank: Escherichia coli )


2 diseases
IDDisease name (Link within this page)Number of trials
53Sjogren syndrome1
78Hypopituitarism1

53. Sjogren syndrome


Clinical trials : 283 Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003749-39-IT
(EUCTR)
15/12/202115/10/2021A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A.A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. - NGF0221 Severe Sjogren’s dry eye disease
MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Oxervate
Product Name: OXERVATE
Product Code: [Recombinant Human Nerve Growth Factor (rhNGF)]
INN or Proposed INN: Cenegermin
Other descriptive name: Recombinant form of human nerve growth factor produced in Escherichia Coli.
DOMPé FARMACEUTICI S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 3United States;Italy

78. Hypopituitarism


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-000356-17-DK
(EUCTR)
19/04/200529/11/2004PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQUSING A NOVEL CAPILLARY BLOOD COLLECTION METHOD - OptimaPHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQUSING A NOVEL CAPILLARY BLOOD COLLECTION METHOD - Optima Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).NutropinAq™ is given as a daily subcutaneous injection dose:GDH: 0,025- 0,035 mg/kg/day,TS : up to 0,05 mg/kg/day, CRI : up to 0,05 mg/kg/day.No dose adaptation will be allowed during the study period unless tolerance or safety mandates a dose reduction.
MedDRA version: 7.0;Classification code 10056438
Trade Name: NutropinAq
Product Name: NutropinAq
INN or Proposed INN: Somatropin
Other descriptive name: Somatropin (INN) recombinant DNA orgin, Escherichia coli
Beaufour Ipsen PharmaNULLNot RecruitingFemale: yes
Male: yes
250Phase 3Finland;Denmark;Italy